Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations

When metastatic tumors driven by drug-targetable genetic mutations become resistant to a targeted therapy drug, the usual practice is to test a single metastatic lesion for new mutations that can guide the selection of next-line therapies. But this strategy may miss additional targetable mutations that arise in different metastases, a new study finds.